Literature DB >> 26235652

Determining comorbidities and quality of life among pediatric survivors of extracorporeal life support.

Heather K Chandler1, Beatriz Teppa2, Khaliah A Johnson3, Courtney McCracken4, James D Fortenberry2, Matthew L Paden2.   

Abstract

PURPOSE: The purpose of this study is to describe health-related quality of life (HRQoL) and the prevalence of comorbidities in pediatric survivors of extracorporeal life support (ECLS) and to determine risk factors for poor HRQoL. MATERIALS: The study design was a retrospective cohort and prospective follow-up study of patients who received ECLS in the pediatric intensive care unit at Egleston Children's Hospital from 2006 to 2013. Quality of life was measured using the Pediatric Quality of Life Inventory (PedsQL 4.0) completed by either parent proxies or the survivors themselves. Clinical data were obtained via review of electronic medical records.
RESULTS: Surveys were sent to 37 parent proxies or survivors with a response rate of 43.2%. Survivors ranged in age from 2 to 21 years with follow-up range of 1 to 7.5 years. Primary respiratory failure due to pneumonia was the reason for ECLS in 81.3%. Mean total PedsQL scores were 73.9 (±21.3) with 11 survivors (69.8%) having a normal quality of life. None of the clinical characteristics (including age, ECLS length, or length of stay) correlated with PedsQL scores. The most commonly reported comorbidities included readmission les than 1 year after ECLS (46.7%) and "problems with school" (25%).
CONCLUSIONS: Survivors of pediatric extracorporeal membrane oxygenation can exhibit good HRQoL scores yet may be at risk for long-term adverse effects, such as lower psychosocial functioning and problems with school. A rigorous prospective investigation of the long-term follow-up of this patient cohort is needed to further evaluate these conclusions and to work toward the best possible outcomes for recipients of this resource-intensive therapy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Extracorporeal membrane oxygenation; Outcome assessment; Pediatrics; Quality of life; Respiratory failure

Mesh:

Year:  2015        PMID: 26235652     DOI: 10.1016/j.jcrc.2015.06.017

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  5 in total

1.  Health-Related Quality of Life in Pediatric Cardiac Patients After Extracorporeal Life Support.

Authors:  Samantha M Meenaghan; Gillian M Nugent; Eithne C Dee; Hazel A Smith; Colin J McMahon; Lars Nolke
Journal:  Pediatr Cardiol       Date:  2021-04-30       Impact factor: 1.655

2.  Improvement in patient-reported outcomes after lung transplantation is not impacted by the use of extracorporeal membrane oxygenation as a bridge to transplantation.

Authors:  Nicholas A Kolaitis; Allison Soong; Pavan Shrestha; Hanjing Zhuo; John Neuhaus; Patti P Katz; John R Greenland; Jeffrey Golden; Lorriana E Leard; Rupal J Shah; Steven R Hays; Jasleen Kukreja; Mary Ellen Kleinhenz; Paul D Blanc; Jonathan P Singer
Journal:  J Thorac Cardiovasc Surg       Date:  2018-02-22       Impact factor: 5.209

3.  Neurologic Outcomes After Extracorporeal Membrane Oxygenation: A Systematic Review.

Authors:  Katharine Boyle; Ryan Felling; Alvin Yiu; Wejdan Battarjee; Jamie McElrath Schwartz; Cynthia Salorio; Melania M Bembea
Journal:  Pediatr Crit Care Med       Date:  2018-08       Impact factor: 3.624

Review 4.  Neurocognitive functioning and health-related quality of life of children after pediatric intensive care admission: a systematic review.

Authors:  José A Hordijk; Sascha C Verbruggen; Corinne M Buysse; Elisabeth M Utens; Koen F Joosten; Karolijn Dulfer
Journal:  Qual Life Res       Date:  2022-03-31       Impact factor: 3.440

Review 5.  Physical Functioning After Admission to the PICU: A Scoping Review.

Authors:  Daniël Bossen; Rosa M de Boer; Hendrika Knoester; Jolanda M Maaskant; Marike van der Schaaf; Mattijs W Alsem; Reinoud J B J Gemke; Job B M van Woensel; Jaap Oosterlaan; Raoul H H Engelbert
Journal:  Crit Care Explor       Date:  2021-06-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.